Skye Bioscience (SKYE) Net Income towards Common Stockholders (2012 - 2026)

Skye Bioscience (SKYE) has reported Net Income towards Common Stockholders for 15 consecutive years, with -$12.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 12.66% year-over-year to -$12.5 million; the TTM figure through Mar 2026 stood at -$57.3 million (down 75.59% YoY), while the FY2025 annual figure was -$55.9 million, down 110.5% from the prior year.
• Net Income towards Common Stockholders improved to -$12.5 million in Q1 2026 per SKYE's latest filing, from -$14.4 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$3.0 million in Q1 2022 and bottomed at -$24.9 million in Q3 2023.
• Historically, Net Income towards Common Stockholders has averaged -$8.9 million across 5 years, with a median of -$7.9 million in 2024.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders slumped 697.68% — and 2024, when it surged 84.37%.
• Skye Bioscience's Net Income towards Common Stockholders stood at -$9.9 million in 2022, then jumped by 55.32% to -$4.4 million in 2023, then sank by 120.51% to -$9.7 million in 2024, then tumbled by 48.18% to -$14.4 million in 2025, then climbed by 13.38% to -$12.5 million in 2026.
• Business Quant data shows SKYE's Net Income towards Common Stockholders at -$12.5 million in Q1 2026, -$14.4 million in Q4 2025, and -$12.8 million in Q3 2025.